6 Ways GLP-1 Drugs Can Support Metabolic Health Beyond Weight Loss
Published on June 8, 2026
GLP-1 (glucagon-like peptide-1) medications don’t just result in weight loss — they can support your metabolic health as a whole. Metabolic health refers to how your body uses energy to function and plays a role in necessary tasks like breathing and digestion.
The GLP-1 hormone occurs naturally in the body. It helps the body regulate blood sugar and slow down digestion so you stay fuller longer. The medication version of the hormone works the same way and has been shown to increase feelings of fullness that can result in weight loss.
But that’s not the whole story. “The benefits of GLP-1 medications reach far beyond the number on the scale,” says Vallari Kothari, MD, an endocrinologist at Montefiore Einstein in New York City.
Here are six ways GLP-1s support metabolic health.
1. Reduce Inflammation
Chronic low-grade inflammation is associated with poor metabolic health outcomes and conditions including diabetes and cardiovascular disorders.
GLP-1s have been shown to reduce signs of inflammation. One systematic review and meta-analysis with over 6,000 participants showed GLP-1s significantly improved levels of C-reactive protein, which is a marker of inflammation, among people with type 2 diabetes. “By cooling this inflammation, GLP-1 medications help restore the cell's ability to ‘hear’ insulin's signal,” Dr. Kothari says, and this effect can improve metabolic health overall.
Poll
How do you feel about the long-term use of GLP-1 drugs?
2. Repair Insulin Response
The body releases naturally occurring GLP-1 when eating, telling the pancreas to release insulin. For many people struggling with their metabolic health, this reaction isn’t working properly, which can lead to blood sugar issues, says Silvana Obici, MD, chief of the division of endocrinology at Stony Brook Medicine and medical director of the Stony Brook University Hospital Diabetes Center in Center Moriches and Lake Grove, New York. “Insulin resistance is strongly associated with weight gain and is a risk factor for coronary artery disease,” she says.
GLP-1 medications can help by releasing insulin only when glucose levels are elevated. “This reduces the risk of both high blood sugar after meals and low blood sugar between meals,” Kothari says. “GLP-1s are not a cure but are the closest thing medicine has to restoring the body's natural blood sugar control system.”
3. Quiet Food Noise
Food noise, or intrusive thoughts about food, sometimes doesn’t have anything to do with real hunger. The feeling of hunger is tied to the way the gut and brain communicate. When working properly, GLP-1 receptors in the brain receive messages that the gut is “full.” “Ultimately, the GLP-1 receptors in the brain help the body control body weight,” Dr. Obici says.
Taking GLP-1 drugs can repair this signal if it is not working properly. GLP-1s have been shown to reduce cravings for unhealthy foods and quiet ongoing thoughts about food. They may even be able to change food preferences or decrease the desire to reach for unhealthy sweets and fatty foods.
The metabolic benefit of the reduced cravings and food noise is weight loss, which improves metabolic issues such as hypertension and uncontrolled blood sugar.
4. Reduce Dangerous Visceral Fat
As mentioned, GLP-1 drugs support metabolic health by contributing to weight loss, which leads to improvements in metabolic health markers such as blood pressure, insulin sensitivity, triglycerides, and cholesterol. One study involving 3,389 people with obesity suggested taking GLP-1s for one year could result in losing 10 percent or more of their body weight.
Notably the medication can lead to visceral fat loss, which is the potentially dangerous fat in the abdominal area that surrounds the organs. Visceral fat may contribute to health issues like heart disease, dementia, asthma, and cancer.
GLP-1 drugs also may limit liver fat accumulation and are being explored as a treatment option for nonalcoholic fatty liver disease, which is common among people with diabetes.
5. Protect the Heart …
Poor metabolic health markers such as insulin resistance increase the risk of heart issues.
GLP-1 drugs are being explored for their potential heart benefits. The U.S. Food & Drug Administration (FDA) approved the GLP-1 drug Wegovy to help reduce the risk of serious heart problems among people who are overweight or have obesity who do not necessarily have type 2 diabetes.
One trial involving nearly 10,000 participants ages 50 and older found people with diabetes taking oral semaglutide (a GLP-1 drug) had a 14 percent reduced risk of major adverse cardiovascular events such as heart attack or stroke. “The mechanisms of how this happens is not fully known yet,” says Amit Zachariah, MD, a cardiologist with Duly based in Schaumburg, Illinois. It could be due to the role of GLP-1s in lowering inflammation or decreasing plaque buildup within the arteries, he adds.
6. … And the Kidneys
GLP-1s may also benefit kidney health. More research needs to be done, but this effect may be due to GLP-1s ability to reduce inflammation or aid in sodium processing, which can result in lowered blood pressure, a marker of metabolic health.
The FDA approved the GLP-1 drug Ozempic to reduce the risk of chronic kidney disease (CKD) progression among those with type 2 diabetes and CKD in 2025.
The Takeaway
- GLP-1s have been shown to benefit metabolic health for reasons other than weight loss.
- In addition to weight loss, research has shown that GLP-1s reduce inflammation, repair the body’s insulin response, quiet food noise, decrease dangerous belly fat, and aid in heart and kidney health.
- These benefits are due to GLP-1s positively affecting blood sugar control, insulin sensitivity, blood pressure, and other markers of metabolic health.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
- Metabolism. Cleveland Clinic. November 20, 2024.
- Yehya NA. GLP-1 and Health: Beyond Weight Loss in the Ozempic Era. UC Davis Health. November 2025.
- Pietzner M et al. Comprehensive Metabolic Profiling of Chronic Low-Grade Inflammation Among Generally Healthy Individuals. BMC Medicine. November 30, 2017.
- Alrasheed T et al. Inflammatory Biomarker Response to GLP-1 Receptor Agonists Versus Other Glucose-Lowering Medications in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology. January 14, 2026.
- Carr K. Boost Your Body’s Built-In GLP-1 System. Old Dominion University. March 2, 2026.
- Fisher J. How Does Ozempic Work? Understanding GLP-1s for Diabetes, Weight Loss, and Beyond. Harvard Health Publishing. April 14, 2025.
- Cook G. Quieting "Food Noise": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits. Cureus. January 5, 2026.
- Farhana A et al. Metabolic Consequences of Weight Reduction. StatPearls. July 10, 2023.
- Metabolic Syndrome. Johns Hopkins Medicine.
- Gasoyan H et al. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Network Open. September 13, 2023.
- Lu J et al. The Effects of GLP-1 Receptor Agonists on Body Composition in Patients with Type 2 Diabetes, Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials. European Journal of Pharmacology. September 15, 2025.
- Taking Aim at Belly Fat. Harvard Health Publishing. March 26, 2024.
- Nevola R et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. January 15, 2023.
- Coulter S. Optimize Your Metabolic Health to Prevent Heart Disease & Stroke. The Texas Heart Institute.
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food & Drug Administration. March 8, 2024.
- McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine. May 29, 2025.
- GLP-1 Receptor Agonists (GLP-1 RAs). National Kidney Foundation. September 16, 2024.
- Anderer S. FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression. JAMA. February 28, 2025.
Meet Our Experts
Sandy Bassin, MD
Medical Reviewer
Member of American College of Lifestyle Medicine
Sandy Bassin, MD, is an endocrinology fellow at Mount Sinai in New York City. She is passionate about incorporating lifestyle medicine and plant-based nutrition into endocrinology,...
Moira Lawler
Author
Moira Lawler is a journalist who has spent more than a decade covering a range of health and lifestyle topics, including women's health, nutrition, fitness, mental health, and trav...